An observational study in Waldenstrom's Macroglobulinaemia Refractory, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by Poitiers University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Waldenstrom Macroglobulinemia with a site in France — 11 open to participants now, 16 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · France.
Among the 41 studies in Waldenstrom Macroglobulinemia with a site in France, this one is one of 4 that started in 2023, is one of 5 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 38th registered.
524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.
Browse Waldenstrom Macroglobulinemia studies →11 of the 41 studies in Waldenstrom Macroglobulinemia with a site in France are open now. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in France, United States, Australia and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in France, United States, Australia and 9 more countries
Ages 18+
Schrödinger, Inc. · Sites in France, United States, Italy and 5 more countries
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Nurix Therapeutics, Inc. · Sites in France, United States, Italy and 5 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 9
First in 1995; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 150 across 40 observational studies indexed under Waldenstrom Macroglobulinemia.
Median enrollment 130 across the 36 interventional studies, 136 across the 5 observational. Of the 21 that completed or were terminated, 7 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 41 have an industry lead sponsor. The 10 most frequent:
Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.
Poitiers University Hospital has 1 study filed under Waldenstrom Macroglobulinemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Waldenstrom Macroglobulinemia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT05131022Nurix Therapeutics, Inc.A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | 2027-01 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT07101328Eli Lilly and CompanyA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | 2027-04 |
| NCT04893564Centre Hospitalier Universitaire, AmiensPrognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 41 studies in Waldenstrom Macroglobulinemia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.
Patients from university hospitals in France (16 center)
Inclusion Criteria:
Exclusion Criteria: none
Observational study
Efficiency
ORR, MRR
Time frame: 2018 to 2025
Tolerance
Adverse events
Time frame: 2018 to 2025
Efficiency in specific population
ORR in CXCR4 mutated patients, ORR in patients previously treated with BTK inhibitors
Time frame: 2018 to 2025
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Dec 2023, 0 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Waldenstrom Macroglobulinemia →
Poitiers University Hospital →